Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm, cytoskeleton Note=Associates with F-actin stress fibers. |
Domain |
PF00261 Tropomyosin |
Function |
Binds to actin filaments in muscle and non-muscle cells. Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction. Smooth muscle contraction is regulated by interaction with caldesmon. In non-muscle cells is implicated in stabilizing cytoskeleton actin filaments (By similarity). Binds calcium (PubMed:1836432). |
Biological Process |
GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0003012 muscle system process GO:0006936 muscle contraction GO:0030048 actin filament-based movement GO:0030049 muscle filament sliding GO:0033275 actin-myosin filament sliding GO:0070252 actin-mediated cell contraction |
Molecular Function |
GO:0003779 actin binding GO:0008307 structural constituent of muscle |
Cellular Component |
GO:0001725 stress fiber GO:0002102 podosome GO:0005862 muscle thin filament tropomyosin GO:0005865 striated muscle thin filament GO:0005884 actin filament GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0005938 cell cortex GO:0015629 actin cytoskeleton GO:0030016 myofibril GO:0030017 sarcomere GO:0030055 cell-substrate junction GO:0030863 cortical cytoskeleton GO:0031941 filamentous actin GO:0032432 actin filament bundle GO:0036379 myofilament GO:0042641 actomyosin GO:0043292 contractile fiber GO:0044448 cell cortex part GO:0044449 contractile fiber part GO:0097517 contractile actin filament bundle GO:0099568 cytoplasmic region |
KEGG |
hsa04260 Cardiac muscle contraction hsa04261 Adrenergic signaling in cardiomyocytes |
Reactome |
R-HSA-397014: Muscle contraction R-HSA-445355: Smooth Muscle Contraction R-HSA-390522: Striated Muscle Contraction |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TPM4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TPM4 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TPM4 in various data sets.
|
Points in the above scatter plot represent the mutation difference of TPM4 in various data sets.
|
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TPM4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TPM4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TPM4. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TPM4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TPM4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TPM4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | TPM4 |
Name | tropomyosin 4 |
Aliases | HEL-S-108; TM30p1; epididymis secretory protein Li 108; tropomyosin-4; Tropomyosin alpha-4 chain |
Chromosomal Location | 19p13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting TPM4 collected from DrugBank database. |
Details on drugs targeting TPM4.
|